New drug combo targets Hard-to-Treat brain tumors
NCT ID NCT05053880
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study investigates whether combining ACT001 (an oral drug) with pembrolizumab (an immunotherapy) can help people with recurrent glioblastoma, an aggressive brain cancer. Participants take the drugs before surgery to remove their tumor, allowing researchers to analyze how the combination affects the tumor environment. The goal is to find a safe dose and see if it improves progression-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ACT001 and pembrolizumab
- What this could lead to
- If it works, this combination could offer a new treatment option for recurrent glioblastoma, potentially slowing tumor progression and extending survival.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply broadly. The drugs can cause side effects like fatigue, nausea, and immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA MULTIFORME(GBM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT MD Anderson Cancer Center, Dept of Neuro-Oncology
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.